Pfizer Inc. (PFE)
24.94
+0.19
(+0.77%)
USD |
NYSE |
Jul 21, 16:00
24.95
+0.01
(+0.04%)
Pre-Market: 05:58
Pfizer Enterprise Value : 193.82B for July 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 21, 2026 | 193.82B |
| July 20, 2026 | 192.73B |
| July 17, 2026 | 194.44B |
| July 16, 2026 | 194.96B |
| July 15, 2026 | 193.13B |
| July 14, 2026 | 189.88B |
| July 13, 2026 | 191.19B |
| July 10, 2026 | 189.43B |
| July 09, 2026 | 189.88B |
| July 08, 2026 | 188.74B |
| July 07, 2026 | 188.86B |
| July 06, 2026 | 186.86B |
| July 02, 2026 | 190.28B |
| July 01, 2026 | 187.78B |
| June 30, 2026 | 188.91B |
| June 29, 2026 | 190.57B |
| June 26, 2026 | 190.11B |
| June 25, 2026 | 186.58B |
| June 24, 2026 | 188.69B |
| June 23, 2026 | 192.56B |
| June 22, 2026 | 194.61B |
| June 18, 2026 | 195.35B |
| June 17, 2026 | 199.40B |
| June 16, 2026 | 200.08B |
| June 15, 2026 | 199.86B |
| Date | Value |
|---|---|
| June 12, 2026 | 201.05B |
| June 11, 2026 | 200.83B |
| June 10, 2026 | 197.58B |
| June 09, 2026 | 198.15B |
| June 08, 2026 | 197.69B |
| June 05, 2026 | 200.08B |
| June 04, 2026 | 198.09B |
| June 03, 2026 | 196.10B |
| June 02, 2026 | 197.29B |
| June 01, 2026 | 197.75B |
| May 29, 2026 | 200.88B |
| May 28, 2026 | 200.65B |
| May 27, 2026 | 201.05B |
| May 26, 2026 | 199.00B |
| May 22, 2026 | 199.29B |
| May 21, 2026 | 199.57B |
| May 20, 2026 | 198.66B |
| May 19, 2026 | 197.92B |
| May 18, 2026 | 196.04B |
| May 15, 2026 | 196.04B |
| May 14, 2026 | 198.43B |
| May 13, 2026 | 199.63B |
| May 12, 2026 | 199.12B |
| May 11, 2026 | 198.77B |
| May 08, 2026 | 198.03B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 636.05B |
| Eli Lilly & Co. | 1.147T |
| Merck & Co., Inc. | 355.22B |
| Bristol Myers Squibb Co. | 160.40B |
| Viatris, Inc. | 32.83B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.709B |
| Revenue (Quarterly) | 14.45B |
| Total Expenses (Quarterly) | 11.75B |
| EPS Diluted (Quarterly) | 0.4688 |
| Gross Profit Margin (Quarterly) | 66.67% |
| Profit Margin (Quarterly) | 18.75% |
| Earnings Yield | 5.23% |
| Operating Earnings Yield | 12.04% |
| Normalized Earnings Yield | 9.303 |